Position in INVA
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$1,631,000
+$231,700 QoQ
Shares Held
70,000
0.0% QoQ
Ownership
0.095%
of shares outstanding
% of Portfolio
0.43%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in INVA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026CHASE INVESTMENT COUNSEL CORP holds $6,273,908 across 5 Biotechnology names. INVA ranks #2 (26.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
26,000 | $1,680,380 | |
| 2 | INVA |
Innoviva, Inc.
This page
|
70,000 | $1,631,000 | |
| 3 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
60,000 | $1,485,600 | |
| 4 | HRMY |
Harmony Biosciences Holdings, Inc.
|
50,000 | $1,400,500 | |
| 5 | VYGR |
Voyager Therapeutics, Inc.
|
19,800 | $76,428 |
All Filings in INVA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,631,000 | 70,000 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $1,399,300 | 70,000 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $1,277,500 | 70,000 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $1,406,300 | 70,000 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $1,269,100 | 70,000 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $1,388,000 | 80,000 | Shares | Sole | 2025-02-05 | |
| 2024-09-30 | $1,544,800 | 80,000 | Shares | Sole | 2024-11-05 | |
| 2024-06-30 | $1,312,000 | 80,000 | Shares | Sole | 2024-08-19 | |
| 2024-03-31 | $1,127,760 | 74,000 | Shares | Sole | 2024-05-02 | |
| 2023-12-31 | $1,090,720 | 68,000 | Shares | Sole | 2024-02-05 | |
| No filing history on record for this holder in this stock. | ||||||